Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 1/2 2Phase NA 1Phase 3 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Mantle-Cell 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Waldenstrom Macroglobulinemia 1Neoplasms 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1B-cell Malignancies 1

Interventions

Dexamethasone 33Cyclophosphamide 31fludarabine 19venetoclax 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × zanubrutinib × Clear all
NCT06634589 2026-06-03

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT06375733 2025-08-12

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Genfleet Therapeutics (Shanghai) Inc.

Phase 1/2 Recruiting
51 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡